The Serum Institute of India’s (SII) first indigenously produced quadrivalent human papillomavirus (qHPV) vaccine against cervical cancer will be considered by the Subject expert committee on Wednesday.
Prakash Kumar Singh submitted the qHPV vaccine commercial licence application to the DCGI on June 8. (director of government and regulatory affairs). Singh’s application to the DCGI highlights the vaccine’s antibody response against HPV types in all dosage and age categories.
Also Read: Normal human brain temperature fluctuates far more than previously considered: Study
According to ANI, the vaccine is scheduled to hit the market by the end of 2022. The qHPV vaccine will be India’s first indigenously curated cervical cancer vaccine.
To assure its early availability in the country, the Pune-based Serum Institute of India submitted for market authorisation after completing a phase 2/3 clinical study with the Department of Biotechnology’s assistance.
Follow Medically Speaking on Instagram
